Surgical outcomes of gastrointestinal stromal tumors of the stomach: A single unit experience in the era of targeted drug therapy

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 941-947

  Huang, Hai ^a,b   Liang, Han ^a   Zhan, Zhong Li ^a   Li, Hui ^a   Ren, Xiu Bao ^a   Hao, Xi Shan ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Department of Surgery   (China)

Author keywords

Adjuvant; Gastrointestinal stromal tumors; Imatinib mesylate; Mitotic index; Molecular targeted therapy; Prognosis; Surgery; Treatment outcome

Indexed keywords

IMATINIB; SUNITINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; MOLECULARLY TARGETED THERAPY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PREOPERATIVE CARE; PROGNOSIS; PYRIMIDINES; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84866285367     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9888-x     Document Type: Article

References (21)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors, definition, clinical, histological, immunohistochemical, and molecular genetic feature and differential diagnosis. Virchows Arch. 2001; 438:1-12.
2. Sircar K, et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol. 1999;l23:377-89.
3. Casali PG, Picci P. Adjuvant chemotherapy for soft tissue sarcoma. Curr Opin Oncol. 2005;17(4):361-5.
4. Demetri GD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-80.
5. Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. N Engl J Med. 2002;346:683-93.
6. Mucciarini C, et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer. 2007;20((7):230.
7. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumours of the stomach: a clinicopathological, immunohistochemical and molecular genetic study of 1765 cases with longterm follow-up. Am J Surg Pathol. 1765;2005(29):52-68.
8. Rutkowski P, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol. 2007;14(7):2018-27.
9. Hassan I, et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol. 2008;15(1):52-9.
10. Takahashi T, et al. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol. 2007;12(5):369-74.
11. Rabin I, et al. Gastrointestinal stromal tumors: a 19 year experience. IMAJ. 2009;12:98-101.
12. Huang H, et al. Different sites and prognoses of gastrointestinal stromal tumors of the stomach: report of 187 cases. World J Surg. 2010;34:1523-33.
13. Fletcher CD, et al. Diagnosis of gastrointestinal stromal tumors. A consensus approach. Hum Pathol. 2002;33:459-65.
14. Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
15. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007;369:1731-41.
16. Huang CC, et al. Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era. World J Surg. 2009;33:828-34.
17. Nikfarjam M, et al. Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy. J Gastrointest Surg. 2008;12:2023-31.
18. Dematteo RP, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669): 1097-104.
19. DeMatteo RP, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007;245:347-52.
20. Verweij J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-34.
21. Gastrointestinal Stromal Tumor Meta-Analysis Group (Meta- GIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28:1247-53.